linjc16/ctgov huggingface dataset:
Effect of ETI Performance on CPR Outcomes

Study Overview
=================
Brief Summary
-----------------
This is a clinical observation study based on analysis of video-clip data of cardiopulmonary resuscitation (CPR) for out-of hospital cardiac arrest (OHCA) in emergency department. Aim of study is to evaluate effect of the factors relating endotracheal intubation (ETI) on the outcome of OHCA patients.

Detailed Description
-----------------
ETI is a standard method for placement of advanced airway during CPR. Frequent attempts or delayed ETI may affect adversely on the outcomes of OHCA. However, there was no known detailed data of explaining this issues. This study tried to evaluate effect of factors of ETI including numbers of trial, time for ETI trial, interruption time and esophageal intubation during CPR on outcomes of OHCA patients.

Official Title
-----------------
Effect of Endotracheal Intubation Performance on the Outcomes in out-of Hospital Cardiac Arrest Patients

Conditions
-----------------
Cardiopulmonary Arrest

Intervention / Treatment
-----------------
* Procedure: Endotracheal intubation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who suffered sudden cardiac arrest and intubated during CPR Exclusion Criteria: case of requesting the do-not-atempt resuscitation patients who were diagnosed as adavanced cancer cardiac arrest by multiple trauma

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Endotracheal intubation|Perform the endotracheal intubation during CPR|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Good Neurologic outcome | survival with good neurologic status (CPC 1-2) after suffering cardiac arrest | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intubation, Cardiopulmonary Arrest
Calcium and Gut Hormones

Study Overview
=================
Brief Summary
-----------------
Gut hormones have therapeutic potential in the prevention and treatment obesity and type 2 diabetes (T2D). Rodent evidence suggests that calcium may stimulate gut hormone secretion. Evidence in humans however, is lacking. This study aims to assess whether the calcium ingestion stimulates gut hormone availability in humans.

Official Title
-----------------
The Effect of Calcium Ingestion on Gut Hormone Secretion.

Conditions
-----------------
Obesity, Diabetes

Intervention / Treatment
-----------------
* Dietary Supplement: Control
* Dietary Supplement: Milk mineral supplement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy men and women age between 18-65 yrs. Able to consume provided supplement. Weight stable for the past 3 month (no change within 3%) Exclusion Criteria: Any previous or current metabolic, cardio-pulmonary or musculoskeletal disease Not between the ages of 18-65 years A body mass index below 18.5 kg/m2 or above 30 kg/m2 (body mass (kg) divided by your height (m) squared) Taking medications that may influence your metabolism Plans to change your lifestyle (diet and/or physical activity) during the study period Not willing to refrain from alcohol containing drinks or unaccustomed exercise one day before the laboratory sessions. Current smoker

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Control<br>Water with artificial sweetener | Dietary Supplement: Control<br>* Water with 80 mg sucralose<br>|
| Experimental: Milk mineral supplement<br>Milk Minerals containing 1000 mg calcium with artificial sweetener and water | Dietary Supplement: Milk mineral supplement<br>* Water with milk mineral supplement (1000 mg calcium), plus 80 mg sucralose<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postprandial plasma GLP-1 area under the curve (mmol/L x 120 min). | Postprandial plasma GLP-1 area under the curve (mmol/L x 120 min). | 120 min | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postprandial plasma GIP area under the curve (mmol/L x 120 min) | Postprandial plasma GIP area under the curve (mmol/L x 120 min) | 120 min | 
| Postprandial plasma PYY area under the curve (mmol/L x 120 min) | Postprandial plasma PYY area under the curve (mmol/L x 120 min) | 120 min | 
| Subjective ratings of appetite (au) | Subjective ratings of appetite (au) | 120 min |
Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease

Study Overview
=================
Brief Summary
-----------------
The Cardiovascular disease research using Linked Bespoke studies and Electronic Records (CALIBER) e-health database was the data resource for this study. CALIBER links patient records from four different data sources: Clinical Practice Research Database (CPRD), MINAP (Myocardial Ischaemia National Audit Project registry) Hospital Episodes Statistics (HES), the Office for National Statistics (ONS).

Detailed Description
-----------------
This study is part of the CALIBER (Cardiovascular disease research using linked bespoke studies and electronic records) programme funded over 5 years from the NIHR and Wellcome Trust. The central theme of the CALIBER research is linkage of the Myocardial Ischaemia National Audit Project (MINAP) with primary care (GPRD) and other resources. The overarching aim of CALIBER is to better understand the aetiology and prognosis of specific coronary phenotypes across a range of causal domains, particularly where electronic records provide a contribution beyond traditional studies. CALIBER has received both Ethics approval (ref 09/H0810/16) and ECC approval (ref ECC 2-06(b)/2009 CALIBER dataset).

Official Title
-----------------
Association of Heart Rate With Cardiovascular Disease Prognosis of Patients With Stable Coronary Artery Disease: A CALIBER Study

Conditions
-----------------
Stable Angina, Myocardial Infarction, Coronary Heart Disease, Heart Failure, Stroke, Death, Sudden, Cardiac, Peripheral Arterial Disease, Atrial Fibrillation, Bleeding

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged >=30 years at study entry ->=1 year registration prior to the 'index date' Exclusion Criteria: Free from previous atherosclerotic events No heart rate measurement after their 'index date' of eligibility to entry the study

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk of cardiovascular diseases in patients with low and high heart rate and stable coronary artery disease | Participants were followed until their first cardiovascular or complication event after their studyentry and after at least one previous cardiovascular event. Hazard ratios will be presenting associations between heart rate (analysed as quintiles and as continuous per 10bpm) and 8 different cardiovascular diseases (including mortality outcomes, complications such as bleeding events and composite cerebrovascular and coronary heart disease endpoints). | expected average of 3 years |
Iron Absorption From GDS Capsules

Study Overview
=================
Brief Summary
-----------------
Slow release iron capsules have been designed based on the gastric delivery system. Iron absorption from those capsules administered with and without meals will be measured using stable iron isotopes.

Official Title
-----------------
Iron Absorption Mechanism From a Slow Release Iron Capsule Using the Gastric Delivery System

Conditions
-----------------
Iron Deficiency

Intervention / Treatment
-----------------
* Dietary Supplement: GDS, no meal
* Dietary Supplement: GDS, meal
* Dietary Supplement: control, no meal
* Dietary Supplement: control, meal


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: female, age 18-50 years, max. body weight 65 kg, serum ferritin < 35µg/l Exclusion Criteria: pregnancy, lactation, regular intake of medication, blood donation or significant blood losses over the past 4 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: GDS, meal<br>GDS, meal | Dietary Supplement: GDS, meal<br>* GDS, meal<br>|
| Experimental: GDS, no meal<br>GDS, no meal | Dietary Supplement: GDS, no meal<br>* GDS, no meal<br>|
| Active Comparator: control, no meal<br>control, no meal | Dietary Supplement: control, no meal<br>* control, no meal<br>|
| Active Comparator: control, meal<br>control, meal | Dietary Supplement: control, meal<br>* control, meal<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fractional iron absorption |  | 2, 4, 6, and 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum isotope appearance |  | day 1, 15, 29 and 33 |
REV 002 Observational Study of the ReVENT Sleep Apnea System: Minimally Invasive Treatment for Obstructive Sleep Apnea

Study Overview
=================
Brief Summary
-----------------
The purpose of this post-market observational study is to assess the effectiveness and patient perception of benefit of the ReVENT Sleep Apnea System in patients diagnosed with Obstructive Sleep Apnea due to primary tongue base closure. The ReVENT Sleep Apnea System is a minimally invasive surgical approach to treat Obstructive Sleep Apnea. The ReVENT Sleep Apnea System consists of an implanter kit and tongue implants. The implants are permanently implanted in the tongue during a minimally invasive outpatient surgical procedure to prevent tongue base closure during sleep.

Official Title
-----------------
ReVENT Sleep Apnea System, a Minimally Invasive Approach to Treat Obstructive Sleep Apnea: a Prospective Multicenter Post-Market Observational Study

Conditions
-----------------
Obstructive Sleep Apnea

Intervention / Treatment
-----------------
* Device: ReVENT Sleep Apnea System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient diagnosed with Obstructive Sleep Apnea due to primary tongue base closure. AHI ≥ 10 and AHI ≤ 40 (at least 90% of apneas and hypopneas must be obstructive). BMI ≤ 32. Confirmation of tongue base closure as the primary source of obstruction with Drug Induced Sleep Endoscopy (DISE). Exclusion Criteria: Patient with prior tongue-base surgery Uvulopalatopharyngoplasty, soft palate surgery, tonsillectomy or minimally invasive RF ablation of the tongue within the last six (6) months. History of mandibular and/or hyoid advancement to treat OSA. Any contraindications as listed in the approved Instructions for Use.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ReVENT implanted group<br> | Device: ReVENT Sleep Apnea System<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction in Apnea-Hypopnea Index (AHI) |  | 3, 6 and 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient perception of benefit as measured by change in daytime sleepiness and sleep-related quality of life |  | 3, 6 and 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obstructive Sleep Apnea, Obstructive Sleep Apnea due to primary tongue base closure, Minimally invasive surgery, ReVENT Sleep Apnea System, Tongue implants
Effect of Treatment With Stress-Doses Glucocorticoid in Patients With Acute Respiratory Distress Syndrome (ARDS)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if stress doses of hydrocortisone improve early outcome in patients who are in early stage of ARDS and with relative adrenal insufficiency.

Official Title
-----------------
Effect of Treatment With Stress-Doses Glucocorticoid on Mortality in Patients With ARDS and Relative Adrenal Insufficiency

Conditions
-----------------
Acute Respiratory Distress Syndrome, Adrenal Insufficiency

Intervention / Treatment
-----------------
* Drug: hydrocortisone
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: within the first 3 days of onset of clinically definite ARDS confirmed by AECC criteria in 1994 18 to 85 year old Exclusion Criteria: pregnancy or lactation tumor or other immunologic disease immunosuppressive drug used bone marrow or lung transplantation primary or secondary disease of adrenal gland hormone used within 3 months refusing conventional therapy be in other clinical tests within 30 days

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: glucocorticoid+RAI<br>stress-dose glucocorticoid treatment, compared to placebo group and ACTH test hints RAI | Drug: hydrocortisone<br>* hydrocortisone 100mg q8h<br>* Other names: cortical hormone;|
| Placebo Comparator: placebo + RAI<br>no glucocorticoid But ATCH test hints RAI | Drug: placebo<br>* normal saline 100ml q8h<br>|
| Active Comparator: glucocorticoid<br>stress-dose glucocorticoid treatment, compared to placebo group and ACTH test does not hint RAI | Drug: hydrocortisone<br>* hydrocortisone 100mg q8h<br>* Other names: cortical hormone;|
| Placebo Comparator: placebo<br>no glucocorticoid But ATCH test does not hint RAI | Drug: placebo<br>* normal saline 100ml q8h<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evidence of clinically definite ARDS confirmed by AECC criteria in 1994 |  | within the first 3 days after surgery onset of ARDS | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute respiratory distress syndrome, glucocorticoid, adrenal insufficiency
Lung Recruitment Maneuver for Predicting Fluid Responsiveness in Children

Study Overview
=================
Brief Summary
-----------------
Lung recruitment maneuver induces a decrease in stroke volume, which is more pronounced in hypovolemic patients. The authors hypothesized that the changes of dynamic variables through lung recruitment maneuver could predict preload responsiveness in pediatric patients with lung protective ventilation

Official Title
-----------------
Study on Variables Able to Predict Fluid Responsiveness Using Lung Recruitment Maneuver in Pediatric Patients Undergoing General Anesthesia

Conditions
-----------------
Hypovolemia

Intervention / Treatment
-----------------
* Diagnostic Test: lung recruitment maneuver


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pediatric patients undergoing general anesthesia under 6 years old Exclusion Criteria: arrhythmia <30%, ejection fraction lung disease

Ages Eligible for Study
-----------------
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: lung recruitment maneuver<br>Heart rate, mean arterial pressure, stroke volume, pulse pressure variations, pleth variability index, and photoplethysmographic waveform were recorded before lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s), during lung recruitment maneuver when stroke volume reached its minimal value. Cardiac index measured before and after volume expansion (10ml/kg saline, 0.9%, infused during 10 min). Patients were considered as responders to fluid administration if cardiac index increased greater than or equal to 15%. | Diagnostic Test: lung recruitment maneuver<br>* Lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| photoplethysmographic waveform |  | change from baseline photoplethysmographic waveform after lung recruitment maneuver within 30 seconds |
Effects of Resistant Starch on Bowel Habits, Fecal Short Chain Fatty Acids and Gut Microbiota in Parkinson Disease

Study Overview
=================
Brief Summary
-----------------
The investigators will investigate the effects of an 8-week resistant starch (RS) supplementation (5 g twice a day) in patients with Parkinson Disease and matched controls on: symptoms of constipation (assessed by clinical scores); fecal short chain fatty acid concentrations (measured by chromatography); gut microbiota composition.

Official Title
-----------------
Effects of Resistant Starch on Bowel Habits, Fecal Short Chain Fatty Acids and Gut Microbiota in Parkinson Disease

Conditions
-----------------
Parkinson Disease

Intervention / Treatment
-----------------
* Dietary Supplement: Resistant starch
* Other: Recommendation with regard to nutrition


Participation Criteria
=================
Eligibility Criteria
-----------------
Main Inclusion Criteria: Written informed to participate For patients: diagnosis of Parkinson Disease Main Exclusion Criteria: Use of antibiotics, steroids or probiotic supplements Chronic or acute disorders of the gastrointestinal tract History of gastrointestinal surgery (other than appendectomy) For healthy controls: Family history of neurodegenerative disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: RS<br>Resistant starch supplementation (5 g twice a day) | Dietary Supplement: Resistant starch<br> <br> |
| Other: No RS<br>PD patients who do not receive resistant starch, but who receive recommendations concerning healthy Nutrition (based on the guidelines of the German Society for Nutrition) | Other: Recommendation with regard to nutrition<br>* Subjects in this arm will receive General recommendations with regard to nutrition based on the guidlines of the German Society for nutrition<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bowel habits | Number of patients with improved bowel habits | 8 weeks | 
| Fecal short chain fatty acid (SCFA) concentrations | Number of patients with either a) increased, b.) unaltered or c) decreased concentration of short chain fatty acids in fecal samples at 8 weeks (compared to baseline) | 8 weeks | 
| Analysis of fecal microbiota composition | Analysis to detect changes between baseline and 8 weeks of resistant starch supplementation | 8 weeks |
Surgical Treatment of Liver Hydatid Cyst (SURGHIDA)

Study Overview
=================
Brief Summary
-----------------
The aim was to analyses the incidence and the independent factors associated with Textbook Outcome following surgical treatment of liver hydatid cysts (LHC).

Detailed Description
-----------------
Textbook outcome (TO) is a composite measure to determine the ideal postoperative period and to assess the quality of surgical care. The aim was to analyses the incidence and the independent factors associated with TO following surgical treatment of liver hydatid cysts (LHC). The investigators conducted a retrospective cohort study of patients operated on for hepatic hydatidosis between January 2006 to December 2021. TO occurred when all the following criteria were fulfilled: no mortality within 90 days, no major complications within 90 days, no reintervention within 90 days and no prolonged hospital stay. Univariable and multivariable analyses were performed to identify factors associated with TO.

Official Title
-----------------
Outcome After Surgical Treatment of Liver Hydatid Cyst

Conditions
-----------------
Echinococcosis, Hepatic

Intervention / Treatment
-----------------
* Procedure: Surgical resection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with liver hydatid cyst treated by total or partial pericystectomy Exclusion Criteria: emergency surgery and simple drainage of cyst

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Surgical group<br>Patients operated on liver hydatidic cyst | Procedure: Surgical resection<br>* Surgical treatment of hepatic hydatidic cyst<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | no mortality within 90 days | 90 days | 
| Morbidity | no major complications within 90 days | 90 days | 
| Re-admission | no re-admissions within 90 days | 90 days |